Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:26:46 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Z:TEVA - TEVA PHARMACEUTICAL INDUSTRIES SPON ADS EACH REP 1 ORD SHS - https://www.tevapharm.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TEVA - Z0.120.00·35.080.234.69-0.1355-0.47,035.6241,96927,31835.00  35.11  34.6137.34  12.46519:53:38Feb 0415 min RT 2¢

Recent Trades - Last 10 of 27318
Time ETExPriceChangeVolume
19:53:38Z34.900.101
19:50:10Z34.6229-0.17718
19:44:06Z34.900.105
18:37:14Z34.900.105
18:04:37Z34.900.109
17:46:46Z34.67-0.132
17:22:13Z34.67-0.1351
17:22:13Z34.67-0.138
17:22:13Z34.67-0.1341
17:22:13Z34.66-0.145

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-04 08:05U:TEVANews ReleaseTeva Canada Announces Approval of Expanded Indication of [Pr]AJOVY(TM) (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
2026-01-28 07:00U:TEVANews ReleaseTeva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
2026-01-27 08:00U:TEVANews ReleaseWill Forte Teams Up with Teva to Get Real About Huntington's Disease with 'Honestly HD'
2026-01-14 17:02U:TEVANews ReleaseAJOVY(TM) (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
2026-01-11 18:00U:TEVANews ReleaseTeva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
2026-01-11 17:15U:TEVANews ReleaseRoyalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
2026-01-11 17:00U:TEVANews ReleaseTeva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
2026-01-05 16:30U:TEVANews ReleaseTeva to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-24 08:36U:TEVANews ReleaseS&P Global Ratings Upgrades Teva to 'BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
2025-12-19 03:40U:TEVANews ReleaseAlvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea(TM)
2025-12-12 16:30U:TEVANews ReleaseTeva Releases Q4 2025 Aide Memoire
2025-12-12 16:30U:TEVANews ReleaseTeva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
2025-12-09 08:00U:TEVANews ReleaseTeva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
2025-11-25 08:10U:TEVANews ReleaseTeva receives European Commission approvals for PONLIMSI(TM) (denosumab) Biosimilar to Prolia(TM) and DEGEVMA(TM) (denosumab) Biosimilar to Xgeva(TM)
2025-11-21 16:30U:TEVANews ReleaseTeva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December
2025-11-19 08:00U:TEVANews ReleaseTeva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges
2025-11-07 18:00U:TEVANews ReleaseAUSTEDO(TM) (deutetrabenazine) tablets and AUSTEDO XR(TM) (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
2025-11-05 07:00U:TEVANews ReleaseTeva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo(TM) and Non-GAAP EPS
2025-11-03 08:00U:TEVANews ReleaseTeva Kicks Off 'The Other TD' to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis